A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV-Reference-Cited by-同舟云学术

A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV

Published:2024-08-30 Issue:1 Volume:13 Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Zhang Zhe¹^ORCID,Chi Xiang-Yang¹^ORCID,Zhang Guan-Ying¹^ORCID,Zhang Zhang¹^ORCID,Lu Song-He²,Li Meng-Jing³,Li Liang-Jun⁴,Zhang Jin-Long¹^ORCID,Shao Fang-Ze¹,Zhang Yue¹,Hou Li-Hua¹^ORCID,Chen Wei¹^ORCID

Affiliation:

1. Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China

2. The Fourth Military Medical University, Xi'an, People’s Republic of China

3. The Eastern Theater Navy, Ningbo, People’s Republic of China

4. The Chinese People's Armed Police Force (PAP) Shanghai Corps, Shanghai, People’s Republic of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2024.2396875

Reference17 articles.

1. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis

2. Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?

3. Organization WH. Interim statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 variant from the WHO Technical Advisory Group on COVID-10 Vaccine Composition 2022. Available from: https://www.who.int/news/item/08-03-2022-interim-statement-on-covid-19-vaccines-in-thecontext-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)-08-march-2022.

4. An observational prospective cohort study of vaccine effectiveness against SARS-CoV-2 infection of an aerosolized, inhaled adenovirus-type-5-vectored COVID-19 vaccine given as a second booster dose in Guangzhou city, China;Wang FZ;J Infect Dis,2024

5. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial